Buy Vinati Organics; target of Rs 1915 Prabhudas Lilladher

Prabhudas Lilladher's research report on Vinati Organics

The company reported revenue of Rs5.5bn in Q2FY26, reflecting a modest 1.5% sequential growth, while remaining flat YoY. As per our discussion with management ~15% revenue growth in FY26 is achievable, primarily driven by volume expansion, with EBITDA margins expected to sustain at ~27%. Benefiting from the decline in raw material prices during H1FY26, margins expanded sharply by 590 bps to 29.9%. ATBS, the company’s flagship highmargin product, accounted for 35% of total revenue and remains oversold, supported by rising demand from the oil & gas sector where it is used as a tertiary oil recovery agent. Phase I of the ATBS capacity expansion has been commercialized this month and will support drive growth going ahead, while Phase II is expected to come online by April’26. The antioxidants segment contributed 12% to the overall revenue mix. New products such as MEHQ and Guaiacol, with a combined peak revenue potential of ~Rs4bn, did not contribute meaningfully in Q2 as samples are still being in approval phase. The ramp-up is expected to be gradual.

Outlook

Additionally, plants for upcoming products like 4MAP, TAA, and PTAP are expected to become operational in Q3FY26. The stock is currently trading at 40x FY27 EPS, we value the stock at 38x Sep’27 EPS and maintain BUY rating.

For all recommendations report, click here